Personalized treatment strategies are increasingly important in managing lung cancer brain metastases, incorporating targeted therapies and immunotherapies. Stereotactic radiosurgery and whole-brain ...

Luspatercept is emerging as a frontline option for lower-risk MDS patients, offering sustained transfusion independence with ...

MPNs involve overproduction of blood cells, while MDS results in poorly formed cells, affecting blood cell function and counts. Diagnosis requires blood tests, bone marrow biopsy, and genetic testing ...

Think of the bone marrow as the body’s factory for blood and immune cells. In myelodysplastic syndromes (MDS), that factory breaks down—producing too few cells, and the ones that do roll off the line ...

The study is among the first to look at the potential impacts of clonal dynamics on patients with lower-risk myelodysplastic syndromes (MDS). However, most of what scientists know about the impact of ...

“We saw really quite remarkable outcomes in a very high-risk MDS population, not only in response rates, but also in blood count improvement, long duration of response and improved overall survival,” ...